NCT00421980
Completed
Phase 3
An Open-Label, Multicentre, Long-Term Extension Study of Etanercept in Ankylosing Spondylitis
Wyeth is now a wholly owned subsidiary of Pfizer0 sites84 target enrollmentJune 2002
ConditionsAnkylosing Spondylitis
DrugsEtanercept
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Ankylosing Spondylitis
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Enrollment
- 84
- Status
- Completed
- Last Updated
- 19 years ago
Overview
Brief Summary
The primary objective of this study was to determine the long-term safety of etanercept in adults with AS who had completed study 0881A3-311-EU.
Detailed Description
This was an open-label, multicenter extension study that was conducted to evaluate the safety and efficacy of etanercept in the treatment of adult subjects with AS who had completed study 0881A3-311-EU. The study consisted of an open-label treatment period of up to approximately 96 weeks.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 3
16.0040 Ankylosing Spondylitis StudyAnkylosing SpondylitisNCT00356356Amgen257
Completed
Phase 3
Pediatric Open-Label Extension Study of Etanercept in Patients With Plaque PsoriasisPediatric Plaque PsoriasisNCT00141921Amgen182
Completed
Not Applicable
Study Evaluating Etanercept in Patients With Rheumatoid Arthritis Who Completed Trial 0881A1-301-EU in SpainRheumatoid ArthritisInflammationNCT00195364Wyeth is now a wholly owned subsidiary of Pfizer93
Completed
Phase 2
Study of the Efficacy and Safety of Etanercept in Adults With VitiligoVitiligoNCT00134368University of Medicine and Dentistry of New Jersey40
Completed
Phase 3
Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trial 016.0012Rheumatoid ArthritisNCT00356590Amgen468